Trial record 12 of 36 for: Open Studies | "Tendinopathy"

Previous Study | Return to List | Next Study

Treatment of Acute and Chronic Ligament and Tendon Injuries With Platelet Rich Plasma

The recruitment status of this study is unknown because the information has not been verified recently.

Verified July 2011 by Stanford University.
Recruitment status was Recruiting

Sponsor:

Information provided by:

Stanford University

ClinicalTrials.gov Identifier:

NCT01406821

First received: July 28, 2011

Last updated: July 29, 2011

Last verified: July 2011

History of Changes

Purpose

Platelet rich plasma has been used in previous studies to stimulate faster healing of torn ligaments and tendons in order to help reduce pain and restore normal function. This study aims to prove that non-operative treatment of acute and chronic ligament and tendon injuries with platelet rich plasma will reduce the time needed for participants to heal these injuries and restore function.

Condition	Intervention
Tendinopathy	Procedure: Ultrasound-guided platelet-rich-plasma (PRP) injection Procedure: Ultrasound-guided dry needling


Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator, Outcomes Assessor) Primary Purpose: Treatment
Official Title:	Randomized, Double-blind Clinical Trial of Platelet Rich Plasma for Treatment of Acute and Chronic Patellar Tendinosis

Resource links provided by NLM:

MedlinePlus related topics: Tendinitis

U.S. FDA Resources

Further study details as provided by Stanford University:

Primary Outcome Measures:

Patient-reported improvement in symptoms at 12 weeks [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Reduction in patellar tendinosis by MRI [ Time Frame: 6 months ] [ Designated as safety issue: No ]


Estimated Enrollment:	100
Study Start Date:	August 2009
Estimated Study Completion Date:	June 2012
Estimated Primary Completion Date:	December 2011 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Sham Comparator: Dry needling Blood will be drawn, and tendon will be penetrated with dry needle. Nothing will be injected into the tendon.	Procedure: Ultrasound-guided dry needling Blood will be drawn, and tendon will be penetrated with dry needle under ultrasound guidance. Nothing will be injected into the tendon.
Experimental: Platelet-rich plasma (PRP) Blood will be drawn, and platelet-rich plasma will be injected into the tendon.	Procedure: Ultrasound-guided platelet-rich-plasma (PRP) injection Blood will be drawn, and platelet-rich plasma will be injected into the tendon under ultrasound guidance.

Detailed Description:

Pre-procedure diagnosis: The appropriate clinical evaluation will be dictated by the examining physician. Minimal pre-procedure studies will include plain radiographs and MRI. All patients will complete a pretreatment questionnaire.

Patients will be randomized and blinded to the treatment regimen.

Method of randomization: Some of the participating subjects will receive platelet rich plasma and others will receive a saline injection. The platelet rich plasma experimental group will have 50cc of whole blood collected via venipuncture and prepared using the standard PRP protocol.

To blind the control group these patients will have a simulated needle stick and 10 ml (2 teaspoons) of blood will be drawn to test for growth factors. No blood will be given back to the patient. For those in the control group their ligament or tendon will be injected with saline. The staff nurse will place the blood (experimental group) or saline (control group) in syringes and the treating physician and patient will be blinded to the treatment.

Platelet rich plasma injections have an equivalent risk profile to routine injections. Those potential risks include skin discoloration, pain at injection site, superficial or deep infection, no relief of symptoms, worsening of symptoms, and damage to nerve and blood vessels. Potential benefits include significant improvement in symptoms and reduction in time for return to function.

Post injection activity: All patients will be non-weight bearing for 24-48 hours after injection. All patients will have physical therapy two times a week according to a standardized protocol.

Follow up at the clinic for all patients will be every other week from week 1-12. All patients will fill out an injury location specific questionnaire, Tegner Activity Scale, short form-12, and visual analog scale for pain. All radiographic studies will be read by one Stanford radiologist blinded to the study groups.

The endpoint for all patients in the study will be twelve weeks.

Eligibility


Ages Eligible for Study:	18 Years to 65 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

-Acute or chronic ligament or tendon injuries

Exclusion Criteria:

Pregnant women,
children,
other injuries that require surgical intervention,
associated fractures,
systemic disease resulting in an immunocompromised state affecting ability to heal soft tissues

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01406821

Contacts


Contact: Amy S Wasterlain	(718) 644-5731	awasterl@stanford.edu

Locations


United States, California
Stanford University School of Medicine	Recruiting
Stanford, California, United States, 94305
Contact: Amy S Wasterlain 718-644-5731 awasterl@stanford.edu
Contact: Jason L Dragoo, MD (650) 721-3430 jdragoo@stanford.edu
Principal Investigator: Dr. Jason L. Dragoo
Study Director: Amy Sarah Wasterlain

Sponsors and Collaborators

Stanford University

Investigators


Study Director:	Amy Sarah Wasterlain	Stanford University
Principal Investigator:	Dr. Jason L. Dragoo	Stanford University

More Information

No publications provided


Responsible Party:	Dr. Jason L. Dragoo, Stanford University School of Medicine
ClinicalTrials.gov Identifier:	NCT01406821 History of Changes
Other Study ID Numbers:	SU-10162010-7109, 16595
Study First Received:	July 28, 2011
Last Updated:	July 29, 2011
Health Authority:	United States: Institutional Review Board

Keywords provided by Stanford University:


tendinopathy PRP platelet-rich-plasma platelet tendinosis tendinitis tendonitis	enthesopathy muscle sport tendon patella patellar tendon

Additional relevant MeSH terms:


Tendinopathy Muscular Diseases Musculoskeletal Diseases Tendon Injuries Wounds and Injuries

ClinicalTrials.gov processed this record on February 27, 2015

To Top